Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 10/20 | 0.76 |
| ▸ | KDR | P35968 | 7/20 | 0.76 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.76 |
| ▸ | RET | P07949 | 3/20 | 0.76 |
| ▸ | BRAF | P15056 | 3/20 | 0.76 |
| ▸ | GSK3B | P49841 | 2/20 | 0.76 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.76 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.76 |
| ▸ | ABL1 | P00519 | 2/20 | 0.76 |
| ▸ | HTR1A | P08908 | 2/20 | 0.76 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.76 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.76 |
| ▸ | KIT | P10721 | 2/20 | 0.76 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.76 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.76 |
| ▸ | FLT1 | P17948 | 2/20 | 0.76 |
| ▸ | MAOA | P21397 | 2/20 | 0.76 |
| ▸ | EPHA1 | P21709 | 2/20 | 0.76 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.76 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3407209 | 0.91 | RAF1 (0.80) | RAF1KDREPHX2RETBRAF | |
| SCHEMBL14715080 | 0.91 | RAF1 (0.79) | RAF1KDREPHX2RETBRAF | |
| SCHEMBL10000735 | 0.89 | RAF1 (0.83) | RAF1KDREPHX2RETBRAF | |
| SCHEMBL26158852 | 0.89 | RAF1 (0.79) | RAF1KDREPHX2RETBRAF | |
| SCHEMBL22473669 | 0.88 | RAF1 (0.77) | RAF1KDREPHX2RETBRAF | |
| SCHEMBL24535359 | 0.88 | RAF1 (0.84) | RAF1KDREPHX2RETBRAF | |
| SCHEMBL3408499 | 0.87 | RAF1 (0.83) | RAF1KDREPHX2RETBRAF | |
| SCHEMBL28948534 | 0.87 | RAF1 (0.83) | RAF1KDREPHX2RETBRAF | |
| SCHEMBL29793192 | 0.87 | RAF1 (0.83) | RAF1KDREPHX2RETBRAF | |
| Sorafenib SCHEMBL14739751 | 0.87 | RAF1 (1.00) | RAF1KDREPHX2RETBRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3409772-B1 | INTRACELLULAR SUBSTANCE TRANSPORT SYSTEM AND USE THEREOF | UNIV HOKKAIDO NAT UNIV CORP (JP) | 2023-06-28 | — | — | EP | disclosed |
| US-11078232-B2 | Preparation and use of molecular site targeted and activated kinase inhibitor | Yafei Shanghai Biology Medicine Science & Technology Co. Ltd. (CN) | 2021-08-03 | — | — | US | disclosed |
| US-11007276-B2 | Intracellular substance transport system and use thereof | NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) | 2021-05-18 | — | — | US | disclosed |
| US-20200140485-A1 | PREPARATION AND USE OF MOLECULAR SITE TARGETED AND ACTIVATED KINASE INHIBITOR | Yafei Shanghai Biology Medicine Science & Technology Co. Ltd. (CN) | 2020-05-07 | — | — | US | disclosed |
| US-20200138973-A1 | INTRACELLULAR SUBSTANCE TRANSPORT SYSTEM AND USE THEREOF | NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) | 2020-05-07 | — | — | US | disclosed |
| US-9078933-B2 | Deuterated omega diphenylurea related compounds and intermediates | SUZHOU ZELGEN BIOPHARMACEUTICAL CO., LTD. (CN) | 2015-07-14 | — | — | US | disclosed |
| US-20140128612-A1 | DEUTERATED OMEGA DIPHENYLUREA RELATED COMPOUNDS AND INTERMEDIATES | SUZHOU ZELGEN BIOPHARMACEUTICAL CO., LTD. (CN) | 2014-05-08 | — | — | US | disclosed |
| US-8669369-B2 | Method and process for preparation and production of deuterated Ω-diphenylurea | SUZHOU ZELGEN BIOPHARMACEUTICAL CO., LTD. (CN) | 2014-03-11 | — | — | US | disclosed |
| US-20130035492-A1 | METHOD AND PROCESS FOR PREPARATION AND PRODUCTION OF DEUTERATED OMEGA-DIPHENYLUREA | SUZHOU ZELGEN BIOPHARMACEUTICAL CO., LTD. | 2013-02-07 | — | — | US | disclosed |
| US-20090012091-A1 | Oximide derivatives and their therapeutical application | KINAGEN, INC. (US) | 2009-01-08 | — | — | US | disclosed |
| US-20090012091-A1 | Oximide derivatives and their therapeutical application | KINAGEN, INC. (US) | 2009-01-08 | — | — | US | disclosed |
| US-20090012091-A1 | Oximide derivatives and their therapeutical application | KINAGEN, INC. (US) | 2009-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012091-A1 | Oximide derivatives and their therapeutical application | CYP11B2, NOS2, HMOX2 | RAF1 3755/4885KDR 1151/4885EPHX2 364/4885 |
| US-20200138973-A1 | INTRACELLULAR SUBSTANCE TRANSPORT SYSTEM AND USE THEREOF | CTSS, CTSA, CTSB | RAF1 615/4885KDR 1262/4885EPHX2 3245/4885 |
| US-20130035492-A1 | METHOD AND PROCESS FOR PREPARATION AND PRODUCTION OF DEUTERATED OMEGA-DIPHENYLUREA | PNLIP, PDXK, PNP | RAF1 1962/4885KDR 3367/4885EPHX2 281/4885 |
| US-11078232-B2 | Preparation and use of molecular site targeted and activated kinase inhibitor | ACP1, PACSIN2, PKN2 | RAF1 127/4885KDR 1924/4885EPHX2 3917/4885 |
| US-20140128612-A1 | DEUTERATED OMEGA DIPHENYLUREA RELATED COMPOUNDS AND INTERMEDIATES | PNLIP, PDXK, DGKK | RAF1 1043/4885KDR 3962/4885EPHX2 755/4885 |
| US-20200140485-A1 | PREPARATION AND USE OF MOLECULAR SITE TARGETED AND ACTIVATED KINASE INHIBITOR | ACP1, PACSIN2, PKN2 | RAF1 122/4885KDR 1954/4885EPHX2 3843/4885 |
| US-11007276-B2 | Intracellular substance transport system and use thereof | CTSS, CTSA, CTSB | RAF1 615/4885KDR 1262/4885EPHX2 3245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.